Abstract: The focus of the present review on regenerative medicine is limited; first, on a few human clinical trials carried out thus far in the urology field, and second, on more basic but important biological progress that regenerative medicine has brought us. Clinical trials for the bladder, urethra and urethral sphincter have been carried out thus far. Reconstruction with autologous cell-seeded biomaterial failed in patients in need of bladder augmentation. The strategy succeeded for urethral reconstruction in patients who might not have required this approach. Sphincter function improvement was attained by cell therapy, but did not equal the conventional standard therapy -the artificial sphincter. The radical progress in regenerative medicine is reported in more basic stem cell technology. The strategy to induce therapeutic cells from inducible pluripotent stem cells has shed novel light on developmental biology. In vitro creation of novel kidney tissue from inducible pluripotent stem cells has been attained. Other kinds of therapeutic cells could also be induced from the inducible pluripotent stem cells. Research should be encouraged to fill the gap between patient needs and what current regenerative medicine can attain.
Introduction: What has regenerative medicine brought to us?
For approximately 20 years, the concept of regenerative medicine has provided hope and the chance for research for clinical and basic scientists in all kinds of medical fields, including urology. For example, a PubMed search for "kidney" and "regeneration" produces 5848 hits, "bladder" and "regeneration" produces 1554 hits, and "urethra" and "regeneration" produces 417 hits. Many of them intend to create novel functional tissue either by cell transplantation, by biodegradable biomaterial or by a combination of both. The use of autologous cell-seeded biomaterials was advocated as "tissue engineering," and caught strong attention of clinicians, giving hope that this methodology would enable the creation of novel artificial organs or tissue that can replace diseased body parts.
The present article aimed to update what has been achieved and is to be expected from recent research of regenerative medicine. Because of the vast number of research articles, as noted above, this article does not cover animal experiments simulating human medicine, which comprise the majority of the literature. Instead, the focus is set onto two limited topics, which are relevant for clinicians. One is about a few human clinical trials carried out thus far in the urology field (Table 1 ). The other is more basic but important biological progress that regenerative medicine brought us.
For the purpose of the study, we carried out a PubMed search with "bladder," "kidney" "urethra" AND "stem cell" or "regeneration," and narrowed down the search by either adding "clinical trial" for the human trials or by adding NOT "tissue engineering" NOT "cell transplantation" NOT "cancer" for basic research. Fortunately or unfortunately, the hit number dramatically decreased. Out of these articles, articles published after 2007, the date of our previous review on bladder regeneration, and considered relevant by the author were classified according to subject topics, and the significance of each article was related with others.
Human clinical trials Bladder
We reviewed a long history of bladder regeneration by biomaterials in our previous review article in 2007, 1 when a group from Boston had just published the result of a pilot clinical studies aimed to augment neurogenic bladder in spina bifida patients with autologous cell-seeded biomaterials. 2 More than 10 years from then, this strategy has not yet proven to be effective. A follow-up study of the Boston trial reported no improvement in bladder compliance of augmented bladder by objective urodynamic analysis.
2,3 Such failure could be interpreted as a failure of vascularity or smooth muscle formation, and for any reason, tissue engineering has not proven to be capable of creating a neobladder yet. 4 
Urethra
Regeneration of the urethra could be considered a less challenging task than the bladder because of its relatively simple structure and function. Indeed, urethral reconstruction might not require autologous cells if the condition permits regenerative regrowth of endogenous urethral tissue on biomaterials. There is a clinical trial report on the use of an acellular bladder matrix graft as the onlay graft of a strictured urethra. 5 According to the authors, the patency of the graft was maintained in eight of nine patients with a healthy urethral bed, but in just two of six with an unhealthy bed. In either situation, a buccal mucosal graft, the standard urethral material today, showed 100% patency. This clinical trial documents well why experiments carried out in healthy animals cannot be readily translated into treatment of diseased human tissue, and also the drawback of decellularized materials.
Can autologous cell seeding overcome this problem? A clinical trial on urethroplasty with cell-seeded materials was carried out in Mexico City by an American team from Wake Forest, the same team that carried out the Boston bladder augmentation trial. 6 They treated five cases of urethral disruption, using biomaterial seeded with autologous cells cultured from the bladder biopsy. The regenerated urethra maintained functional patency for at least 3 years. Despite the successful result, we should note that a few factors other than cell transplantation could be involved in the outcome. First, these five cases had bulbar lesions, and were candidates for end-to-end anastomosis in standard practice, rather than substitution by non-urethral tube material. Second, biomaterial alone could regenerate the urethra, as our group showed in a rabbit model of a 2-cm defect. 7 In the healing process, such a bridging graft can pull both anastomotic ends, even when the graft itself shrinks. The clinical trial did not treat penile urethral reconstruction, where substitution is definitively required. 8 Therefore, the trial of a tissue-engineered urethra could not be judged as a clear success until further study is reported in patients truly in need of them.
Urethral surgeons are indeed in urgent need of materials that can repair challenging cases of adult urethral stricture or pediatric hypospadias. To date, the "success" of a tissue-engineered urethra under the limited conditions attained thus far does not warrant application of this methodology to patients in real need of urethral replacement.
Sphincter
While creation of a novel organ might be an ambitious task to be tested clinically, more focused application of cell transplantation has been attempted for sphincter regeneration. Clinical trials for restoring a damaged urethral sphincter have been carried out by cell transplantation of autologous myocytes, muscle-derived stem cells and adipose tissue-derived cells. [9] [10] [11] However, after examining the results of these clinical trials, one review article concluded that cell-based therapy, as practiced today, is "a safe but ineffective method" for stress urinary incontinence treatment.
12 Such a negative conclusion was lead to in comparison with what standard therapy -an artificial urethral sphincter -can attain. For example, one Japanese group presented 1-year follow-up data of 11 male patients after periurethral injection of adipose-derived cells, showing objective improvement, with an approximately 60% reduction of leakage in the 24-h pad-test and increased urethral pressure profiles. In this case, improvement in objective parameters does not mean satisfactory clinical continence, which an artificial sphincter can attain. The success of regenerative medicine in clinical trials is judged from the standpoint of "medical success," but not from that of "statistical success." Biological progress brought to us by regenerative medicine
Relevance of stem cell biology for regenerative medicine
Radical advances in stem cell biology have taken place, boosted by the urgent need for tissue regeneration in numerous disease contexts. iPS cell technology has been developed by Japanese researchers (Fig. 1) . 14, 15 The key point of this technology is that reprogramming of differentiated cells can be attained by introducing three or four defined transcription factors into already differentiated somatic cells. These reprogrammed pluripotential cells can theoretically differentiate to any kind of cells if the developmental process can be mimicked by the introduction of transcription factors or the modification of culture conditions. iPS cells are fundamentally different from ES cells, which requires disruption of an embryo. The rapid progress of iPS cells is now reaching the clinical trial phase for regeneration of retinal cells in ophthalmology 16 and dopaminergic neurons in neurosurgery. 17 One important feature of iPS cell technology is that it provides a unique research platform for developmental biology. The iPS cells are theoretically able to differentiate to any kind of organ tissue if the developmental process can be replicated. Therefore, developmental biology, which used to be a science confined to academic relevance, has become an important part of biotechnology for inducing therapeutic cells out of stem cells. As another interesting aspect, some researchers also seek to induce therapy cells directly from somatic cells, bypassing the reprogramming process back to stem cells, termed "transdiffentiation."
18 Although, presently, iPS-derived tissue has cured few patients as yet, it has stimulated biologists toward the discovery of genes working in various aspects of organogenesis.
Kidney regeneration
An increasing number of patients with end-stage renal disease are treated by chronic dialysis or kidney transplantation. 19 Among all the organs, kidney regeneration is considered to be one of the most challenging tasks. The network structure of the nephron is so complicated that few people believe that it could be artificially engineered. Therefore, researchers in this field inevitably aim to replicate natural kidney development.
The discovery of the nephrogenic mesenchyme by a Japanese group is a typical example of such a scenario. 20, 21 In the search for primordial nephrogenic cells, the group discovered that the nephrogenic mesenchyme exist in a caudal, but not cranial, part of an embryo. It was indeed a revolutionary discovery, as researchers had postulated that the nephrogenic mesenchyme should exist cranial to the ureteral bud, inferred from cranial migration of the developing kidney to the upper abdomen. That Copernican Revolution in developmental biology enabled the induction of a functional nephron unit out of the iPS cells in vitro.
Creation of cells with specific functions
Another strategy of utilizing iPS cells for regenerative medicine is to use iPS cells for inducing cells with more specific functions. Although still experimental, erythropoietin-producing cells induced from iPS cells could effectively treat druginduced renal anemia in vivo. 22 Theoretically, such an approach could be applied to any kind of endocrinological cells, and therefore, cells producing adrenal and testicular steroid hormones are potential candidates in the urological field.
One drawback in this kind of approach is that the new therapy needs to overcome conventional pharmacological therapy. Drug therapy is already established with erythropoietin, testosterone, cortisol or aldosterone. Cell-based therapy might not be able to replace drug therapy, as long as safety, efficacy and, hopefully, cost-effectiveness are superior to the drugs.
Stem cell biology and lower urinary tract
Despite a long history of experimental bladder augmentation by biomaterials, a scientific basis for bladder regeneration is scarce. Such lack of basic biology might be one reason why a surprising increase in bladder regeneration studies, as initially noted, has brought little virtual progress to us. However, as limitations of the conventional animal experimentbased approach have become evident, a few researchers have become aware of the importance of basic bladder biology. The presence of urothelial progenitor cells in the trigone was reported by a bladder regeneration group in Holland. 23 The regenerative process of the urothelium, which remains quiescent in an uninjured condition, is studied from various angles, including an oncological aspect. 24 Cell biology of sphincter muscle cells might deserve attention, as such research could uncover the secret of regeneration. 25, 26 The secret of regeneration should be overlapped with the secret of organ development, and regenerative medicine of the lower urinary tract might not progress further without progress in the basic biology of the lower urinary tract. Conclusions: Can regenerative medicine cure those who should be cured?
Can regenerative medicine cure those who should be cured? This question can be ironically converted as, "Is a cure necessary when regenerative medicine can cure somebody?" Researchers should design animal experiments to show the statistical difference between a study group and controls, but such a difference does not confer a cure of diseased patients, as we described in examples.
The creation of a neo-organ is not a promised goal. Nevertheless, there are numerous patients who do need a cure for their urological diseases. One should definitively encourage the researchers who honestly admit the gap between what patients need and what we can do today, and strive to progress science, instead of excessive clinical hope.
